CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
Posaconazole strongly inhibits the liver enzyme CYP3A4 (posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, and posaconazole label, US Food and Drug Administration, FDA), and this enzyme breaks down most ergot alkaloids (posaconazole label, FDA). As a result, posaconazole may raise dihydroergotamine blood levels and cause ergotism, poisoning by ergot alkaloids (posaconazole SmPC, EMA, and label, FDA). Higher dihydroergotamine levels raise the risk of vasospasm leading to ischaemia of the brain and limbs (dihydroergotamine labels, FDA). Serious and life-threatening ischaemia has been reported when dihydroergotamine was combined with strong CYP3A4 inhibitors, including antifungals (dihydroergotamine labels, FDA).
Symptoms
With excess dihydroergotamine, the arms and legs become numb, tingling and painful, the fingers and toes turn cold, pale or bluish, and pulses in the arms and legs weaken or disappear (dihydroergotamine label, US Food and Drug Administration, FDA). Leg ischaemia causes cramping and pain in the legs and hips, heaviness in the leg muscles, burning pain in the feet at rest, and coldness and colour change in one or both legs. Brain ischaemia causes slurred speech and sudden weakness (dihydroergotamine label, FDA). Severe poisoning causes nausea, vomiting, abdominal pain, respiratory depression, a rise and then usually a fall in blood pressure, confusion, delirium, seizures and coma (dihydroergotamine label, FDA). Persistent vasospasm in people with poor circulation can lead to gangrene or death (dihydroergotamine label, FDA).
Management
The combination is contraindicated (posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA; posaconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; posaconazole label, US Food and Drug Administration, FDA). Dihydroergotamine is contraindicated with strong inhibitors of the enzyme CYP3A4 (dihydroergotamine labels, FDA), and posaconazole is a strong inhibitor of this enzyme (posaconazole SmPC, EMA, and label, FDA). Dihydroergotamine is not authorised in Spain, so there is no Spanish SmPC for it. If the patient has nevertheless taken both drugs and develops signs of vasospasm (numb, cold, pale or bluish fingers, cramping and pain in the legs, slurred speech or sudden weakness), stop dihydroergotamine at once and get emergency medical help (dihydroergotamine labels, FDA). In overdose, stop dihydroergotamine, support and monitor vital functions, and observe the patient for at least 24 hours or for as long as symptoms persist (dihydroergotamine label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Posaconazol (nº registro 90284), sección 4.3 (2025)– AEMPS, CIMA, nº registro 90284, sección 4.3
- FDA: Noxafil (posaconazole) prescribing information (2026)– FDA, DailyMed, Noxafil (Merck Sharp & Dohme), setid b073b082-7b57-4423-8c06-4fd4263d6f84, versión 56, revisión 02/2026, secciones 4.2, 4.3, 4.4, 4.5, 5.2 y 7.2
- FDA: ATZUMI (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid 0982a44a-dc0c-75c0-e063-6394a90a6d6c, revisión 06/2026 (versión 3), secciones 4, 5.5, 5.6 y 7.2
- FDA: TRUDHESA (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid b81397b0-910d-4eb4-8fee-a9a3c9d94d63, revisión 09/2026 (versión 7), secciones 4 y 7.2
- EMA: Ficha técnica: Posaconazol (EU/1/05/320), sección 4.3 (2026)– EMA, Noxafil (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 105320002, consultada 10/2026, secciones 4.3, 4.4 y 4.5